Chat with us
Research Assistance
Online
  • Please enter your first name.

North America Plasmid Dna Contract Manufacturing Market Size & Outlook

The plasmid dna contract manufacturing market in North America is expected to reach a projected revenue of US$ 535.3 million by 2030. A compound annual growth rate of 19% is expected of North America plasmid dna contract manufacturing market from 2024 to 2030.

  • HC Outsourcing
    • CMO/CDMO
      • Plasmid DNA Contract Manufacturing Market Outlook
Revenue, 2023 (US$M)
$158.0
Forecast, 2030 (US$M)
$535.3
CAGR, 2024 - 2030
19.0%
Report Coverage
North America

North America Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)

North America Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Prism AI by Grand View ResearchFree to try

Ask a question about the plasmid dna contract manufacturing market

Every figure cited from GVR research

North America plasmid dna contract manufacturing market highlights

  • The North America plasmid dna contract manufacturing market generated a revenue of USD 158.0 million in 2023.
  • The market is expected to grow at a CAGR of 19% from 2024 to 2030.
  • In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
  • Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
  • Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.


North America data book summary

Market revenue in 2023USD 158.0 million
Market revenue in 2030USD 535.3 million
Growth rate19% (CAGR from 2023 to 2030)
Largest segmentCell & gene therapy
Fastest growing segmentCell & Gene Therapy
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCell & Gene Therapy, Immunotherapy
Key market players worldwideCharles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster


Other key industry trends

  • In terms of revenue, North America region accounted for 48.6% of the global plasmid dna contract manufacturing market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 203.4 million by 2030.

The high prevalence of diseases in the region, rise in research funding, and presence of numerous pharmaceutical & biopharmaceutical firms in the region are all key factors driving the Plasmid DNA (pDNA) contract manufacturing market in North America.

The development of advanced treatments has had a significant impact on the biopharmaceutical sector's transformation as well as the paradigm of treating a number of serious & rare diseases. The growing popularity of Cell & Gene Therapies (CGTs) also propels growth of the market in the region.

In fact, more than 400 companies in North America are actively working to develop and research on CGTs. Among these therapies, many widely use pDNA as a vector for gene therapies and DNA vaccines against infectious, acquired, & genetic diseases, including cancer and COVID-19.

No credit card required*

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Plasmid DNA Contract Manufacturing Market Companies

NameProfile# EmployeesHQWebsite
Lonza Group LtdView profile 18,000Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002www.lonza.com
Thermo Fisher Scientific IncView profile 122,000168 Third Avenue, Waltham, MA, United States, 02451www.thermofisher.com
Charles River Laboratories International IncView profile 21,400251 Ballardvale Street, Wilmington, MA, United States, 01887www.criver.com
Boehringer IngelheimView profile 10001+Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europewww.boehringer-ingelheim.com/
TriLink BioTechnologiesView profile 251-500San Diego, California, United States, North Americawww.trilinkbiotech.com/
BioCinaView profile 101-250Thebarton, South Australia, Australia, Oceaniawww.biocina.com/
Viva BiotechView profile 1001-5000Shanghai, Shanghai, China, Asiawww.vivabiotech.com.cn/
VGXIView profile 101-250The Woodlands, Texas, United States, North Americavgxii.com/
PlasmidFactoryView profile 11-50Bielefeld, Nordrhein-Westfalen, Germany, Europeplasmidfactory.com/
Esco AsterView profile 11-50Singapore, Central Region, Singapore, Asiaescoaster.com

North America Plasmid DNA Contract Manufacturing Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Plasmid DNA Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.


Cell & Gene Therapy was the largest segment with a revenue share of 60.38% in 2023.

Horizon Databook has segmented the North America plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.




The high prevalence of diseases in the region, rise in research funding, and presence of numerous pharmaceutical & biopharmaceutical firms in the region are all key factors driving the Plasmid DNA (pDNA) contract manufacturing market in North America.

The development of advanced treatments has had a significant impact on the biopharmaceutical sector's transformation as well as the paradigm of treating a number of serious & rare diseases. The growing popularity of Cell & Gene Therapies (CGTs) also propels growth of the market in the region.

In fact, more than 400 companies in North America are actively working to develop and research on CGTs. Among these therapies, many widely use pDNA as a vector for gene therapies and DNA vaccines against infectious, acquired, & genetic diseases, including cancer and COVID-19.

  • North America Plasmid Dna Contract Manufacturing Market Application Outlook (Revenue, USD Million , 2018-2030)
    • Cell & Gene Therapy
    • Immunotherapy
    • Others
  • North America Plasmid Dna Contract Manufacturing Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
    • Cancer
    • Infectious Diseases
    • Autoimmune Diseases
    • Cardiovascular Diseases
    • Others
  • North America Plasmid Dna Contract Manufacturing Market End User Outlook (Revenue, USD Million , 2018-2030)
    • Pharmaceutical and Biotechnology Companies
    • Research Institutes

Reasons to subscribe to Plasmid DNA Contract Manufacturing Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Plasmid DNA Contract Manufacturing Market Outlook databook

  • Our clientele includes a mix of Plasmid DNA Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America Plasmid DNA Contract Manufacturing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Plasmid DNA Contract Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.

North America Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)

No Access Stack Chart

North America plasmid dna contract manufacturing market statistics, by application, 2018-2030 (US$M)

No Access Pie Chart

North America plasmid dna contract manufacturing market statistics, by country, 2018-2030 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more